Pharmafile Logo
Pharmafocus logo
Advanced Search

Vertex

Showing 15 posts of 39 posts found.

vertex-headquarters

Vertex scores EU approval for cystic fibrosis drug Kalydeco in R117H+ children and adolescents

June 10, 2020
Research and Development, Sales and Marketing Kalydeco, Vertex, cystic fibrosis, ivacaftor, pharma

Vertex has revealed that it has secured a new approval from the European Commission for its therapy Kalydeco (ivacaftor) in …

News

Vertex’s Kalydeco seizes EU CHMP recommendation for Kalydeco in R117H+ cystic fibrosis

May 1, 2020
Medical Communications, Sales and Marketing Europe, Kalydeco, Vertex, cystic fibrosis

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given its recommendation for the approval …

News
vertex-headquarters

Data revealed on novel CRISPR/Cas9 gene-editing therapy for first two severe haemoglobinopathy patients

November 19, 2019
Manufacturing and Production, Research and Development Vertex, crispr, pharma

Vertex and CRISPR Therapeutics have unveiled the first interim Phase 1/2 data demonstrating the safety and efficacy of the investigational …

News
vertex-headquarters

Vertex’s cystic fibrosis portfolio to be made available across Northern Ireland and Wales

November 13, 2019
Research and Development, Sales and Marketing Kalydeco, NHS, Orkambi, Symkevi, Vertex, pharma

After drawn out negotiations and much discontent among cystic fibrosis (CF) patients and their advocates, Vertex has announced that a …

News
vertex-headquarters

FDA approves Vertex’s Trikafta in new indication, now potentially covering 90% of cystic fibrosis patients

October 23, 2019
Research and Development, Sales and Marketing FDA, Trikafta, Vertex, cystic fibrosis, pharma

The FDA has granted marketing authorisation to Vertex’s Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF), it …

News
vertex-headquarters

Vertex cystic fibrosis drugs become available in Scotland after NHS rejection

September 12, 2019
Sales and Marketing SMC, Vertex, cystic fibrosis

Two potentially life-changing cystic fibrosis drugs are to become available for a potential pool of 400 patients in Scotland just …

News
vertex-headquarters

Scotland turns down Vertex’s Orkambi

August 13, 2019
Manufacturing and Production Orkambi, SMC, Scotland, Vertex, cystic fibrosis, pharma

The Scottish Medicines Consortium (SMC) has turned down Vertex’ cystic fibrosis drug Orkambi on the grounds that it is not …

News
vertex-headquarters

FDA expands Vertex’s cystic fibrosis drug Symdeko in paediatric patients

June 24, 2019
Sales and Marketing FDA, Symdeko, Vertex, cystic fibrosis, pharma

Vertex has announced that the FDA has chosen to expand the existing authorisation on its cystic fibrosis (CF) therapy Symdeko …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

June 14, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, GSK, J&J, JJ, Otsuka, Pfizer, Purdue, Sanofi, Vertex, pharma

Pfizer supressed research showing their arthritis drug Enbrel reduced the risk of Alzheimer’s. This was the big revelation this week! …

News
vertex-headquarters

MPs discuss breaking Vertex’s IP rights to bring Orkambi to UK

June 11, 2019
Research and Development Orkambi, Vertex, access, house of commons, pharma, pricing

MPs yesterday discussed circumventing Vertex’s patent on cystic fibrosis medicine Orkambi (Lumacaftor/ivacaftor) as a means of breaking the deadlock and …

News
vertex-headquarters

Parents of children with cystic fibrosis start Orkambi buyers club

June 5, 2019
Research and Development NHS, Orkambi, Vertex, cystic fibrosis

Parents of children with cystic fibrosis have started an Orkambi buyers’ club to import generic versions of Vertex’s drug from …

News

The price of access: Can the NHS afford Orkambi?

April 29, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, NHS, NICE, Orkambi, UK, Vertex, access, cystic fibrosis, feature, pharma, pricing

The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in …

Feature
vertex-headquarters

Vertex destroyed nearly 8,000 packs of Orkambi in 2018

March 28, 2019
Medical Communications, Sales and Marketing Briatin, Orkambi, UK, Vertex, cystic fibrosis

Vertex destroyed nearly 8,000 packs of the $272,000 a year cystic fibrosis drug Orkambi in 2018, the company said in …

News
vertex-headquarters

Vertex doubles Q4 profits, angering cystic fibrosis drug advocates in UK

February 11, 2019
Sales and Marketing Orkambi, Vertex, cystic fibrosis, pharma

Despite ongoing controversy surrounding the currently stalled negotiations between Vertex and the NHS to make its cystic fibrosis (CF) drug …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

February 1, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, England, NHS, Purdue, Vertex, insys, israel, oncology, pharma, top 10

Scandal dominated this week’s news after Sunrise Lee, a stripper turned Insys sales rep was alleged to have given a …

News

Latest content

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023